A Randomized Clinical Trial Comparing the ELLIPTA and HandiHaler Dry Powder Inhalers in Patients With COPD: Inhaler-Specific Attributes and Overall Patient Preference

Figures & data

Figure 1. Subject disposition.AE, adverse event.

Table 1. Patient baseline demographics and disease characteristics (ITT population).

	Total (N = 212)
Age, years	65.1 (9.15)
Sex, n (%)
Female	103 (49)
Race, n (%)
African American/African heritage	22 (10)
American Indian or Alaska native	1 (<1)
Asian	1 (<1)
Japanese/East Asian heritage	1 (<1)
White	188 (89)
Ethnicity, n (%)
Hispanic or Latino	2 (<1)
Not Hispanic or Latino	210 (>99)
Height (cm)	168.7 (10.15)
Weight (kg)	82.9 (24.57)
BMI (kg/m^2)	29.0 (7.78)
Smoking history
Current smoker, n (%)	93 (44)
Former smoker, n (%)	119 (56)
Pack-years	54.8 (28.09)

Data are mean (standard deviation) unless otherwise specified.

BMI, body mass index; ITT, intent-to-treat; SD, standard deviation.

Figure 2. Overall^* preferences for each inhaler-specific attribute of ELLIPTA and HandiHaler mITT, modified intent-to-treat; PP, per-protocol.^*Based on pooled data from both inhaler use sequences; ^***p < 0.001.

van der Palen J, Thomas M, Chrystyn H, Sharma RK, van der Valk PD, Goosens M, Wilkinson T, Stonham C, Chauhan AJ, Imber V, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: Comparison of ELLIPTA with other inhaler devices. NPJ Prim care Respir Med [Internet]. 2016 Nov 24 [cited 2017 Jun 7];26(1):16079. Available from: http://www.nature.com/articles/npjpcrm201679. doi:10.1038/npjpcrm.2016.79. PMID:27883002.

 PubMedGoogle Scholar